Overview

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia

Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of the efficacy and safety of withdrawal of tyrosine kinase inhibitors after previous two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission
Phase:
Phase 2
Details
Lead Sponsor:
Masaryk University
Treatments:
Dasatinib
Imatinib Mesylate